<Anchor> The Korean

government has also entered an import approval process for the "Remdesivir", which was urgently approved as a treatment for corona19 in the United States.

It is used by a patient and how we can live as long as we want.

<Reporter> The

Ministry of Food and Drug Safety (KFDA) has launched a procedure to approve the special import of 'Remdesivir' as a treatment for corona19.

The goal is to make urgently needed drugs available on a limited basis without sufficient clinical trials.

[Lee Eui-kyung / Director of the Ministry of Food and Drugs: The clinical results are positive and ready for introduction.] In

a multinational clinical trial involving domestic patients, Remdecivir reduced the length of hospital stay from 15 days to 11 days and reduced the fatality rate from 11.9% to 7.1 Even lowering to%, no serious side effects were commonly found.


However, it was not decided how long it would be given to which patient, but a member of the Central Clinical Commission of Infectious Diseases stated that the guidelines were based on three clinical trials published in the United States and China.

In principle, 5 days is administered to patients in need of oxygen treatment within 10 days after the onset of symptoms. On the 5th day of administration, an additional 5 days are administered when the condition is severe, such as ventilator or Ekmo treatment. The room is promising.


[Chaegyu a / sikyak treatment drug policy manager: (Jeremiah Pradesh Vir A) can be a therapeutic option (select) about the point and general patients to reduce the severe patients with treatment duration -

usually five days administered 10 days of administration The treatment effect was better than the group, and the rate of side effects was lower, but treatment for 10 days in the severe patients had a lower mortality rate.

As the decision to use domestic patients in the pandemic, that is, the global epidemic situation, a strategy was needed to get enough supplies at a stable price.

The Ministry of Food and Drug Safety (KFDA) said that the supply price of Remdesivir has not been decided yet, and it will quickly grasp domestic demand and negotiate with the manufacturer.

(Video coverage: Jang Un-suk, Video editing: Ho-jin Kim)